Diabetes Pathophysiology and Treatment Strategy Updates

Type 2 diabetes involves progressive insulin resistance combined with declining beta-cell function over time, leading to worsening glycaemic control despite ongoing treatment. This progressive nature often necessitates treatment intensification beyond initial oral therapy as the disease advances. Understanding this trajectory supports proactive rather than reactive treatment planning. Early and appropriate intensification can help reduce long-term complication risk associated with sustained hyperglycaemia.

Treatment intensification typically progresses from lifestyle modification and initial oral therapy toward combination oral agents, and eventually to injectable therapies including GLP-1 receptor agonists or insulin as needed. The specific pathway depends on individual patient factors, including comorbidities, weight considerations and hypoglycaemia risk. Recognising the appropriate timing for each escalation step is a key focus of ongoing clinical education. Delayed intensification can prolong exposure to inadequate glycaemic control.

Individualised glycaemic targets account for factors such as patient age, comorbidities, disease duration and hypoglycaemia risk, rather than applying a uniform target to all patients. This approach balances the benefits of tight glycaemic control against the risks of over-treatment in vulnerable patients. Individualised targets also inform decisions around treatment intensity and monitoring frequency. This principle is increasingly reflected in contemporary diabetes management guidance.